Trial Profile
A Multicenter Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BFORE
- Sponsors Avillion; Pfizer
- 15 Jun 2023 Results of post-hoc pooled analysis of B1871006 (NCT00261846), B1871007 (NCT00811070), B1871039 (NCT02228382, BYOND) B1871048 (NCT03128411), B1871008 (NCT00574873) & (B1871040, NCT01903733) assessing effect of BMI on the safety of bosutinib in patients with previously treated or newly diagnosed CML, presented at the 28th Congress of the European Haematology Association.
- 13 Dec 2022 Results assessing the impact of comorbidities on efficacy and safet of Bosutinib reporting the results by Charlson Comorbidity Index (CCI)after 5 years of follow up, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results assessing the efficacy and safety (after 5-Years Follow-up) of bosutinib versus imatinib after 5-years follow-up in a subpopulation of US patients, presented at the 64th American Society of Hematology Annual Meeting and Exposition.